INTRODUCTION
Oral colon-specific drug delivery system (CDDS) has been developed as one of the site-specific drug delivery systems. This delivery system comprises a combination of one or more controlled release mechanisms leading to hardly any release of the drug in the upper part of the gastrointestinal (GI) tract, but rapid release in the colon following oral administration [1] [2] [3] .
Polysaccharides are widely used in oral drug delivery systems because of the simplicity to obtain the desired drug delivery system and drug release profile, by the control of cross-linking, insolubility of crosslinked beads in gastric environment and broad regulatory acceptance [4] [5] [6] . The inability of the GIT enzymes to digest certain plant polysaccharides is taken advantage in developing a colon-specific drug delivery system. Various polysaccharides are being evaluated for colon targeting such as pectin (PEC), guar gum, gum ghatti, dextran, chitosan, and xylan [7, 8] .
Indomethacin (IDM) is a nonsteroidal antiinflammatory drug (NSAID) that can exhibit chemoprotective effects against tumors and reduce the risk of colon cancer [9] [10] [11] . Despite recent advances in NSAIDs formulations, the design of targeted delivery systems to improve the efficacy and reduce side effects of NSAIDs continues to be a focus of much research [12] [13] [14] .
This study was aimed at the design and development of controlled release matrix tablets of IDM using hydrogenated castor oil (HCO) and PEC, with the aid of 3 2 full factorial design, to achieve a colon targeted 24 h release profile in vitro.
EXPERIMENTAL Materials
Indomethacin (γ-polymorphic form) (IDM) was kindly supplied by Pharco Pharmaceuticals, Alexandria, Egypt. Also used were pectin (PEC, BDH Co, England). hydrogenated castor oil (HCO, Girnar Industries, Gujarat, India, as well as talc and magnesium stearate (BDH Chemicals Ltd, Poole, UK). All other chemicals used were of reagent grade.
Fourier transform infrared spectroscopy
Fourier transform infrared (FTIR) spectrum of IDM and physical mixtures (1:1:1) of IDM with other excipients (PEC and HCO) as well as different formulations prepared by hot fusion method, namely F4 and F6, were performed to find out any possible drug-excipients interaction using KBr pellet method using Perkin-Elmer FTIR series (model-1615) spectrophotometer between 4000-450 cm -1 .
Preparation of indomethacin solid dispersions by hot fusion method
Hydrogenated castor oil was melted in porcelain evaporating dish using a water bath at 60 °C. Indomethacin and pectin were mechanically mixed to form homogenous mixture and then this mixture was added with continuous stirring (HCO, PEC and the drug were used in the required ratios for each preparation) to get a homogeneous dispersion. The obtained molten mass was then allowed to cool down and solidify. Subsequently, the mass was ground, pulverized and passed through a 60-mesh sieve (< 300 µm). The obtained powders were stored in desiccators at room temperature until use.
Preparation of indomethacin matrix tablets
The solid dispersion was directly compressed using a single punch tablet machine (Erweka, Germany) fitted with 9 mm diameter normal flat punches and die sets. Relatively constant tablet hardness was held around 10 kg. An amount of solid dispersion equivalent to 50 mg of IDM was compressed after the addition of 3 % w/w (of tablet weight) of lubricant (Talc: Magnesium stearate 9:1). Tablet weight was 300 ± 5 mg. Tablets were then subjected to in vitro release study.
In vitro release studies
The in vitro release study of IDM tablets was performed using USP apparatus II (Erweka, Germany) fitted with paddle (50 rpm) at 37 ± 0.5 °C using 0.1 N HCl (pH 1.2, 900 mL) as a dissolution medium for the first 2 h, followed by pH 6.8 phosphate buffer solutions for further 10 h. At the predetermined time intervals, 5 mL samples were withdrawn and replaced with fresh preheated dissolution medium, then the withdrawn samples were filtered through a 0.45 μm membrane filter and assayed spectrophometrically at 270 nm using a UV spectrophotometer (Shimadzu, Kyoto, Japan). Cumulative drug release was computed from a standard calibration curve. The dissolution profile of all batches were fitted to various models including zero order, first order [15] , Higuchi [16, 17] , Korsmeyer and Peppas [18] to ascertain the kinetics of drug release (Equations 1-4, respectively). C = K 0 t ………………………………….. (1) where, K 0 is zero-order rate constant expressed in units of concentration/time and t is the time.
Log C = LogC 0 -K 1 t/2.303 …………… (2) where C 0 is the initial concentration of drug and K 1 is first order constant.
where, KH is the constant reflecting the design variables of the system. M t /M ∞ = Kt n ………..…………………… (4) where M t /M ∞ is fraction of drug released at time t, K is the release rate constant.
Optimization of variables using 3 2 full factorial design
A 3 2 full factorial design was employed to systematically study the joint influence of the effect of independent variables X 1 and X 2 on the dependent variable. In this design, 2 factors were evaluated, each at 3 levels, and experimental trials were performed at all 9 possible combinations. The amounts of HCO (X 1 ) and PEC (X 2 ) were selected as independent variables in 32 full factorial design, while Y1, Y2 and Y3 (% drug release after 2, 24 h and time required to release 25 % drug, respectively) were taken as dependent variables. The formulation layout for the factorial design batches (F1-F9) is shown in Table 1 .
Response surface analysis
Two dimensional (2-D) contour plot and three dimensional (3-D) surface response plots where constructed based on the model polynomial function using Minitab program version 17. These plots are very useful to see interaction effect on the factor of the response.
Statistical analysis
The results were analyzed by using Graph Pad software version 6. One way analysis of variance (ANOVA) with Tukey's multiple comparisons post hoc was used to test for significant differences, and differences were considered significant at p < 0.05. Figure 1 demonstrates the characteristic IR peaks of pure IDM which were compared with peaks obtained from the respective physical mixture (1:1:1) as well as with F4 and F6. It was observed that characteristic peaks of IDM appears with identical or with minor differences, at frequencies 3370.33 and 1717.14 cm [19] . It can be seen that the peaks of the prepared formulations F4 and F6 as well as the physical mixture are the sum of the characteristic peaks of the drug and the corresponding excipients used. The spectra of Fig. 1 indicated the compatibility between the drug and the two polymers used for preparation of IDM matrix tablets by hot fusion technique.
RESULTS

Compatibility of IDM with the polymers
Preliminary trial
In a preliminary study, batches containing various concentrations of HCO alone and in combination with the other polymer (PEC) were prepared to check their influence on in vitro characterization of compressed matrix tablets. It was found that as the concentration of HCO increased, the drug release for upper GIT was retarded till 6.79 %. It was found that tablets containing combinations of HCO with PEC retarded the drug release in pH 1.2 and gave faster drug release in pH 6.8. Figure 2 illustrates the release profile of IDM from the different matrix tablets prepared by direct compression of the solid dispersion of the drug into the polymers. The release profile of IDM from the 9 batches showed drug release in pH 6.8 ranged from 0-2.5 % after 2 h while, drug release after 24 h ranged from 41 % to 76 %. The release of the drug after 24 h for all the tablets prepared was based upon the mechanical mixtures of IDM and pectin. However, tablets prepared using high concentration of HCO (187.5 mg) showed IDM release of < 67 % after 24 h whereas, the tablets prepared with medium (166.66 mg) and low (125 mg) concentrations of HCO released about 70 and 76 % of the drug, respectively. As the amount of HCO increased from 125 mg (F1, F2 and F3) to 187.5 mg (F7, F8 and F9), the drug release was significantly decreased (p < 0.05). The in vitro release profiles of drug from all these formulations can be best expressed by Higuchi equation as the correlation coefficient (R 2 ) values were the highest (0.820 for F4 to 0.923 for F5) as compared with the other release kinetic models studied.
In vitro drug release
Full factorial design
According to the 3 2 factorial designs, various trial formulations of IDM matrix tablets were prepared by direct compression method using ingredients stated in Table 1 . The results of the regression analysis indicated that these models were significant for all response parameters ( (5) where, Y is the dependent variable, b 0 is the intercept representing the arithmetic mean response of the nine runs, and b 1 is the estimated coefficient for the factor X 1 . The main effects (X 1 and X 2 ) represent the average result of changing one factor at a time from its low to high values. The interaction terms (X 1 X 2 ) show how the response changes when 2 factors are simultaneously changed. The polynomial terms (X 1 2 and X 2 2 ) are included to investigate nonlinearity. Table 1 indicate that the drug release profile is strongly dependent on the selected independent variables. The fitted equations relating the responses, Y1, Y2 and Y3 to the transformed factor are shown in Table 2 .
The data from Fig 2 and data of
The polynomial equations can be used to draw conclusions after considering the magnitude of coefficient and the mathematical sign it carries whether it is negative or positive. Table 2 shows the results of regression analysis which was performed to identify insignificant factors. Data were analyzed using Minitab 17 program. 
Response surface analysis
Three-dimensional response surface plots and their corresponding contour plots to estimate the effects of the independent variables (factors) on each response investigated were presented in Fig. 3A , B and C. The three-dimensional response surface plots and corresponding contour plots relating drug release indicated the deceased values of Y1, Y2 and increased values of Y3 with the increment of the two independent variables X 1 and X 2 (amounts of HCO, and PEC in IDM matrix tablets). 
DISCUSSION
The slower release from the solid dispersion matrices using HCO alone can be due to almost complete coating of the IDM particles by HCO melted in the process of hot fusion. Further batches were prepared using combinations of HCO and PEC to check the synergistic effect of various combinations on the drug release.
On this preliminary study a factorial design was employed to find out the best combination of HCO and PEC that minimizes the further drug release in upper GIT and upon arrival to colon that releases the drug as quickly as possible.
In vitro drug release
It was expected that the penetration of the dissolution medium into the matrix will be low and hence, the release of the drug occurs at a slower rate. So, as the concentration of HCO increased the thickness of the drug particles coating increased leading to higher extent in drug release retardation.
From Fig. 3 it was concluded that at higher percentage of PEC, the tablets could remain intact in the physiological environment of stomach and small intestine but once tablets enter into the colon, it is acted upon by polysaccharidases, which degrade the PEC and hence promote release the drug in the colon.
The two criteria upon which the optimized formulations for colon delivery were selected are the percentage zero release in acidic medium (pH 1.2) and the slow release of the drug in pH 6.8. Formulations F7, F8 and F9 fulfilled the previous two requirements. The slow release in vitro indicated reasonable release in vivo in presence of the pectinase enzyme. It was reported that the drug release in presence of rate cecal content could be increased from 20 -30 % A B C [20] . Consequently that 100 % drug release rate could be attained within 16 h, which is the normal residence time of a solid dosage form in the colon [21] . Therefore, it can be concluded that F7, F8 and F9 matrix tablets (Fig. 2C) would be considered as promising sustained release formulations of IDM for colon delivery. Higuchi's kinetics explains why the drug diffuses at a comparatively slower rate (0.043 for F4 and 0.083 for F6) as the distance for diffusion increases. All the formulations showed slope (n) values ranging from 0.494 for F4 to 0.618 for F6.
The n values for all formulations indicated nonFickian diffusion which refers to a combination of both diffusion and erosion controlled-drug release.
Traditionally, pharmaceutical formulators develop various formulations by changing one variable at a time but the method is time-consuming. However, many experiments not succeed in their purpose because they are not properly thought out and designed, and even the best data analysis cannot compensate lack of planning. Therefore, it is essential to understand the influence of formulation variables on the quality of formulations with a minimal number of experimental trials and subsequent selection of formulation variables to develop an optimized formulation using established statistical tools for optimization [22] .
In case of Y1, the results of multiple regression analysis showed that both the coefficients b 1 and b 2 (coefficient of factors X 1 and X 2 , respectively) bear a negative sign indicating a release retarding effect. It was anticipated that both matrix forming polymers would have synergistic retardant effect. The highly hydrophobic HCO and the gel forming polymer PEC ensured the expectation of very slow drug release rate. So increasing the amount of the two polymers in the formulation decreased the amount of drug released into the dissolution media. Depending on the value of the coefficient of factors, it can be stated that both polymers (X 1 and X 2 ) were responsible for the obtained value of Y1 but X 2 has more pronounced effect on drug release retardation.
The amount of drug released after 24 h is an important parameter for prominent drug release from sustained release matrix formulation. The data of the factorial equation for Y2 showed that the coefficient factor of X 2 is negative indicating a release retarding effect. The delay in drug release may be conditioned by the proportion of PEC in the formulations. As shown in Fig 2, as the amount of PEC increased in the tablet matrices, the drug release was decreased after 24 h.
The time required for 25 % drug release was selected for comparison between the different formulations. The coefficient factor of X 1 is negative indicating that Y3 was strongly dependent on HCO as a matrix forming material. The time needed for melting of the hydrophobic polymer was the primary factor affecting the initial drug release.
Response surface methodology is a widely proficient approach in the development and optimization of drug delivery devices [23, 24] . The three-dimensional response surface plot is very useful in learning about the main and interaction effects of the independent variables (factors), whereas two-dimensional contour plot gives a visual representation of values of the response [23, 24] .
From the response surface analysis, it was found that the values decreased with the increase of two independent variables (amount of HCO and PEC). The higher viscosity due to increasing amount of hydrophilic polymer used, PEC may promote the formation of highly viscous gel upon contact with aqueous fluids of the dissolution medium, which would retard the drug release rate from these IDM matrix tablets.
CONCLUSION
Indomethacin matrix tablets for colon delivery containing a combination of the polymers, HCO and PEC, hold good promise for drug release retardation. Successful 3 2 full factorial design, development, and optimization of IDM tablets has been achieved in this study.
